A new version of the Eyebrain Tracker has been developed incorporating specific analyses that can accurately quantify the eye motricity anomalies associated with multiple sclerosis.
EyeBrain has launched the new software version in a bid to assist with MS diagnoses as well as helping to monitor patients’ progress and verifying the effect of therapies prescribed by medics.
Serge Kinkingnéhun, company chairman, said: “There is currently no tool that provides an accurate quantification of the development of multiple sclerosis. The EyeBrain Tracker can thus be a valuable aid for neurologists in the treatment of their patients, especially regarding the choice of drugs and their dosing.”
People with multiple sclerosis often suffer from transitory or permanent neuro-ophthalmological problems, with disruptions in eye movements affecting between 6- 80% of patients. The most frequently observed peculiarities are alterations in tracking movements and anomalies in patients’ ability to focus and hold a look.
These eye movement indicators are valuable for determining the state of patients suffering from the condition and for monitoring the development of the disease.
The new EyeBrain Tracker makes it possible to analyse a sensitive and quantifiable marker of anatomical function, namely eye motricity, including internuclear ophthalmoplegia. Since this marker is reproducible, it can provide quantified monitoring of the progress of the disease.
